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Themost frequently diagnosed cancers in women are the estrogen receptor (ER)-positive
breast cancer subtypes, which are characterized by estrogen dependency for their
growth. The mainstay of clinical treatment for this tumor relies on the modulation of
ERα action or on the suppression of estrogen biosynthesis via the administration of
Selective ERα Modulators/Down-regulators (SERMs/SERDs) or aromatase inhibitors,
respectively. Nevertheless, de novo and acquired resistance to these therapies frequently
occurs and represents a major clinical concern for patient survival. Recently, somatic
mutations affecting the hormone-binding domain of ERα (i.e., Y537S, Y537N, D538G)
have been associated with endocrine resistance, disease relapse and increased mortality
rates. Hence, devising novel therapies against these ERα isoforms represents a
daunting challenge. Here, we identified five molecules active on recurrent Y537S ERα
polymorphism by employing in silico virtual screening on commercial databases of
molecules, complemented by ER-transactivation and MTT assays in MCF7 and MDA-
MB-231 breast cancer cells expressing wild type or mutated ERα. Among them, one
molecule selectively targets Y537S ERα without inducing any cytotoxicity in breast cell
lines. Multi-microseconds (4.5 µs) of biased and unbiased molecular dynamics provided
an atomic-level picture of the structural, thermodynamics (i.e., binding free energies) and
the kinetic (i.e., dissociation free energy barriers) of these active ligands as compared to
clinically used SERM/SERDs upon binding to wild type and distinct ERα variants (Y537S,
Y537N, D538G). This study contributes to a dissection of the key molecular traits needed
by drug-candidates to hamper the agonist (active)-like conformation of ERα, normally
selected by those polymorphic variants. This information can be useful to discover mutant
specific drug-candidates, enabling to move a step forward toward tailored approaches
for breast cancer treatment.
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INTRODUCTION
Breast Cancer (BC) is the most frequent cancer type and the
second leading cause of death in women, representing 25% of all
cancers. In ∼70% of the BC cases detected after the menopause,
cellular proliferation is mediated by estrogens (1; Figure 1)
binding to their specific nuclear hormone receptor [Estrogen
Receptor α (ERα, ESR1)] (Fanning and Greene, 2019).
This latter is a ligand-activated transcription factor, which
upon estrogen binding, decreases apoptosis and/or promotes
cell proliferation, ultimately playing a pro-oncogenic role.
Hence, in the most diffused BC type cell proliferation relies
on the expression of ERα, and on the presence of blood
circulating estrogens, being hence classified as ER sensitive
(ER+). Gold standard endocrine treatments against ER+
BC consist in suppressing estrogen biosynthesis, via the
administration of aromatase inhibitors, or in counteracting
ERα pro-oncogenic action via the drugging of selective ERα
modulators (SERMs) or downregulators (SERDs). Namely,
SERMs [tamoxifen and its most abundant metabolite endoxifen
(END)] act as antagonists, occupying the estrogen binding
site and inducing a conformational change of ERα toward
an inactive conformation. SERDs [fulvestrant (FULV)],
instead, also foster ERα ubiquitination and degradation
(Fanning et al., 2016; Pavlin et al., 2018).
Similarly to other nuclear receptors, ERα presents a puzzling
tridimensional structure which atomic-level organization
remains controversial (Huang et al., 2018). This is composed out
FIGURE 1 | Structures of 17β-estradiol (1), tamoxifen (2), endoxifen (3), fulvestrant (4), AZD-9496 (5), and compounds 9, 13, 19, 20, 21 which are the identified
drug-candidates active against Y537S ERα.
of five distinct functional domains (Supplementary Figure 1),
among which only the structures of the DNA-binding domain
and the ligand-binding domain (LBD) have been characterized.
The LBD is active as a homodimer with each monomer hosting
a ligand binding cavity (LBC). The LBD crystal structures
(Supplementary Figure 2) revealed that upon binding of
an agonist or an antagonist molecule, helix 12 (H12) can
undergo a conformational switch between the active and
inactive form, respectively (Joseph et al., 2016). In the agonist
(active) state, H12 faces helices H3, H5/6, and H11, closing
the LBC (Supplementary Figure 2A; Robinson et al., 2013).
Conversely, in the antagonist (inactive) form, H12 rearranges,
as a consequence of SERM/SERD-binding, moving toward the
groove lined by H3 and H5 (Supplementary Figure 2B; van
Kruchten et al., 2015; Joseph et al., 2016).
In the last decades, SERMs have been proved to be highly
beneficial, substantially decreasing the mortality rates of woman
affected by BC cancer type by 25–30 %. The most effective ERα
antagonists in clinical use are: (i) tamoxifen (2; Figure 1), a
SERM, which in spite of its beneficial action in breast tissues, is
plagued by agonistic effects in peripheral ones (endometrium),
and is active through its metabolite, endoxifen (3; Figure 1), and
(ii) FULV (4; Figure 1), a potent SERD (Nilsson and Gustafsson,
2011; van Kruchten et al., 2015) characterized, however, by poor
solubility. This makes its administration arduous and therefore
probably limiting its efficacy. These adjuvant therapies are
administered over extended time frame (5–10 years) to control
tumor growth, or, even, to prevent disease in case of BC-prone
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genetic profiles. Nevertheless, after prolonged exposure to these
therapies, tumors evolve by adapting to the pharmacological
pressure. Distinct studies highlighted a stunningly complex,
composite, and multifactorial genomic landscape as responsible
of tumor refractoriness to treatments (Spinello et al., 2019b). This
has mostly been associated to an alteration of mitogen activated
kinase pathway (MAPK) or of a deregulated estrogen receptor
transcriptional activity (Razavi et al., 2018). This latter takes place
when ERα acquires new structural traits, eventually leading to
resistance and relapse to therapies. Scaringly, almost 50 % of
all ER+ BC patients, initially benefiting from first-line therapy,
will eventually develop resistance after prolonged treatments
(acquired resistance). This ultimately results in a shortening of
their survival time.
It is nowadays well-established (Merenbakh-Lamin et al.,
2013; Robinson et al., 2013; Toy et al., 2013; Jeselsohn et al.,
2014) that distinct ERα polymorphisms (mERαs), located in
the vicinity of LBC (i.e., E380Q), between H9 and H10, or
in the loop connecting H11 and H12 (i.e., L536Q, L536R,
Y537C, Y537N, Y537S, and D538G), are recurrently observed
in metastatic BC patients relapsing after extended treatments
regimens. The most abundant ERα polymorphisms observed in
LBD are D538G (occurrence of 21–36 % of cases (Jeselsohn et al.,
2014; Chandarlapaty et al., 2016; Toy et al., 2017), Y537N (5–33
%) (Jeselsohn et al., 2014; Toy et al., 2017), and Y537S (13–22
%) (Jeselsohn et al., 2014; Chandarlapaty et al., 2016; Toy et al.,
2017). This latter remains the most aggressive isoform (survival
rate of 20 months as compared to 26 of D538G) (Chandarlapaty
et al., 2016). Most of these mutations are insensitive to tamoxifen,
while still responding to FULV. As such, tumors proliferation
still depends on ERα expression, underlying the still unmet
oncological need of a complete inhibition/abrogation of its
signaling pathway (Busonero et al., 2019).
Targeted therapy counteracting mERα is a current object of
intense preclinical and early clinical interest, as also evidenced
by the significant number of studies aiming at identifying orally
bioavailable SERDs, eventually able to overcome resistance (De
Savi et al., 2015; Fanning et al., 2018; Hamilton et al., 2018;
Sharma et al., 2018; Kahraman et al., 2019; Scott et al., 2019).
Among these GDC-810, AZD9496 (5; Figure 1) (hereafter AZD,
a drug in preclinical use as oral SERD, for which a first clinical
study have been recently accomplished) (Weir et al., 2016;
Hamilton et al., 2018), and LSZ102 have been identified (Scott
et al., 2019).
Aiming at selectively targeting specific and aggressive ERα
variants, we have recently meticulously annotated the structural
and dynamical alterations induced to ERα structure by each
recurrent polymorphism, disclosing that each of them triggers
the acquisition of a different agonist-like (intrinsically active)
conformation of H12. As a result, tumors bearing these
isoforms proliferate irrespectively of estrogen production, with
SERMs and aromatase inhibitors’ efficacy being lost after their
appearance (Spinello et al., 2019b). Since these ER+ BC cells
are sensitive to FULV and AZD, we also performed extensive
MD simulations typifying the structural features responsible
of distinct efficacy of FULV and AZD on mutant (m)ERα, as
opposite to END.
Stunningly, our computational assays disclosed that the
FULV and AZD’s elongated shape, owing to their aliphatic
and carboxylic moiety, respectively, was the key structural
determinant counteracting the acquisition of an H12 agonist-
like conformation (Fanning et al., 2016; Pavlin et al., 2018).
Understanding the structural signature needed by drugs able
to effectively fight metastatic and refractory BC types was a
necessary prerequisite for the rational discovery of mutant-
specific SERMs/SERDs. Building on this knowledge, here, we
performed virtual screenings on existing database of molecules,
and we tested their efficacy on MCF7 and MDA-MB-231 cell
lines harboring Wild Type (WT) and Y537S, D538G, and Y537N
ERα variants. As a result, we identified five molecules able to
counteract the enhanced transcriptional activity of Y537S ERα
isoform, with one being non-cytotoxic and preferentially active
toward the Y537S variant. The structural and dynamical impact
of the five active molecules, as well as their thermodynamic
and kinetic properties (of the best molecule) were also explored
via biased and unbiased classical Molecular Dynamics (MD)
simulations, and compared with those of END, AZD, and FULV
in order to dissect the source of their distinct efficacy profiles.
These outcomes may lead toward the discovery of isoform-
selective drug-candidates, providing a therapeutic option for




The NCI (https://cactus.nci.nih.gov/download/nci/) library
Release 4 Files Series—May 2012 (containing 265,242 structures)
was used for virtual screening (VS) studies. Compounds
were filtered using the Schrodinger Suite 2017-1 Ligfilter
tool (2017). In order to eliminate molecules possessing poor
absorption and permeation we applied Lipinski’s rule of
five (Lipinski et al., 2001). Further, filtering was applied to
compounds bearing more than 10 rotatable bonds, since
high ligand flexibility implies higher entropic contributions
and reduces oral availability (Veber et al., 2002). Next,
QikProp (2017) was employed to predict LogP values of
the compounds to assess information on their solubility
in water.
After ligand preparation in silico screening of the library was
performed on different mERα structures. Namely, in order to
account for receptor’s flexibility in the screening we considered
five different ERα conformations as target structures (Pavlin et al.,
2018). These were selected from the populated cluster extracted
from 500 ns-long classical MD simulations trajectories of AZD
and FULV in complex with the Y537S, Y537N, and D538G
isoforms obtained in our previous study (Pavlin et al., 2018). In
this respect, we employed two conformations for Y537S ERα (in
complex with AZD and FULV), one for Y537N (in complex with
FULV, since conformation of this mutant complex with AZD
was similar to that of Y537S), and two structures for D538G
(in complex with AZD and FULV). A van der Waals (vdW)
radius scaling factor of 0.80 Å for protein and ligands atoms
having a partial charge < 0.15 was used to account for protein
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flexibility. Size of the box for in silico screenings was determined
by considering the residues interacting with different antagonists
placed inside the binding site and those residues pinpointed as
critical for antagonizing ERα activation in our previous work
(Pavlin et al., 2018).
In order to obtain a set of promising ligands for experimental
testing, we followed two protocols of VS. First, a workflow
based on three subsequent steps of docking with increasing
level of accuracy for each ERα conformation, was adopted by
using the Glide program (Friesner et al., 2004). Namely, (i)
a fast high-throughput virtual screening (HTVS) was initially
performed in order to efficiently select promising ligands among
∼220,000 of compounds from the pre-filtered NCI library;
(ii) 10 % of the best ranked ligands (∼22,000 structures per
each ERα conformation) were retained and a single precision
(SP) docking calculation was done; (iii) the top 10 % of
the resulting compounds (∼2,200 structures per each ERα
conformation) were screened using the extra precision (XP)
protocol. This latter should eliminate false positives by using a
more extensive sampling and more accurate scoring functions.
END, AZD, and FULV were also docked to assess the quality
of our results as reported in Supplementary Table 1. The
molecules resulting from the screening were sorted according
to GlideScore scoring function. The selection criterion for
further investigation was that the screened compounds had
docking score lower than −8.5 kcal/mol and that displayed
favorable interactions with at least one of the five mERαs
target structures (i.e., two structures extracted from the MD
trajectory of Y537S ERα in complex with AZD and FULV,
one for Y537N in complex with FULV, and two structures
for D538G in complex with AZD and FULV). This was done
in order to find a good compromise between the number of
molecules selected for experimental screening and the quality
of the docking score. Moreover, our reference molecules FULV
and AZD exhibit on the target structure the same range of
docking score values.
In the second protocol, we initially performed ligand-based
screening using the CANVAS program (Duan et al., 2010; Sastry
et al., 2010). Here the searching criteria were based on the
scaffold that antagonist should possess. The latter was defined
considering the common structural features that an effective
SERD should have according to our previous study (Pavlin
et al., 2018), more precisely, selected ligand should have scaffold
based either on the END scaffold or on the tri-membered ring
scaffold of AZD in order to stabilize ligand inside LBC, together
with a polar tail that is able to form hydrogen bonds (H-
bonds) with the H11-12 loop. The 415 selected ligands were
then screened to all five mERαs conformations by using XP
protocol. In this second case, the cut-off docking score for
selection of ligands was −7.5 kcal/mol, and the ligands were
selected only when displaying favorable interactions with at least
two distinct mERα structures among the five target structures
used and at least one was within the cut-off range. These
molecules were available as donation of the National Cancer
Institute USA. Other known activities of the five molecules
observed to be active on Y537S in this study are reported in
Supplementary Table 7.
Reagents, Antibodies, and Plasmids
17β-estradiol was purchased from Sigma (St. Louis, MO,
USA). Antibodies against ERα and GAPDH were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Yellow
fluorescent protein (YFP)-tagged expression constructs, YFP-
WT, YFP-Y537S, YFP-Y537N and YFP-D538G ERα were
generated as previously described (Gelsomino et al., 2016,
2018) XETL plasmid, containing an estrogen-responsive
element, was provided by Dr. Picard (University of Geneva,
Geneva, Switzerland).
Cell Cultures
Human MCF-7 and MDA-MB-231 BC cells were acquired
in 2015 from American Type Culture Collection, stored
and cultured according to supplier’s instructions. Cells were
used within six-months after frozen-aliquot resuscitations and
regularly tested for Mycoplasma-negativity (MycoAlert, Lonza,
Basilea, Switzerland).
Immunoblot Analysis
Equal amounts of proteins were resolved on 10% SDS-PAGE
as previously described (Giordano et al., 2016). The antigen-
antibody complex was revealed using the ECL System (Bio-rad,
Hercules, CA, USA). Images were acquired using Odissey FC
from Licor (Lincoln, Nebraska, USA). Blots are representative of
three independent experiments.
ERα Transactivation Assay
ERα transactivation assay was performed as previously reported
(Barone et al., 2011). Briefly, MCF-7 and MDA-MB-231 cells
(50,000/well) were plated in phenol red-free with 5 % charcoal-
stripped FBS in 24-well plates. After 24 h, cells were co-
transfected with 0.5 µg of reporter plasmid XETL plus 0.1
µg of YFP-tagged expression constructs and 20 ng of TK
Renilla luciferase plasmid as an internal control. Transfection
was performed using the Lipofectamine 2000 reagent (Life
Technologies, Carlsbad, CA, USA) as recommended by the
manufacturer. Six hours after transfection, the medium was
changed and the cells were treated as indicated for 24 h.
Firefly and Renilla luciferase activities were measured using
a Dual Luciferase kit (Promega, Madison, WI, USA). The
firefly luciferase data for each sample were normalized on the
basis of transfection efficiency measured by Renilla luciferase
activity (Rizza et al., 2014). Data represent three independent
experiments, carried out in triplicate.
MTT Cell Viability Assay
1,000 cells were plated into 96-well plates in phenol red-
free medium containing 5 % charcoal-stripped FBS. After
24 h, cells were exposed to the different treatments as
indicated. One day later, cell viability was assessed by (3-
(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium-Bromide)
(MTT, Sigma-Aldrich) as described (Covington et al., 2013).
Results are expressed as fold change relative to vehicle-treated
cells. Data represent three-independent experiments, performed
in triplicate.
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Real-Time RT-PCR Assays
Total RNA was extracted from cells using TRIzol reagent
(Life Technologies). Purity and integrity of the RNA were
confirmed spectroscopically and by gel electrophoresis before
use. One microgram of total RNA was reverse transcribed
in a final volume of 20 µL using the RETROscript kit (Life
Technologies) and cDNA was diluted 1:3 in nuclease-free water.
The evaluation of TFF1, CTSD, CCND1 and MYC mRNA
expression was performed by real-time RT-PCR, using SYBR
Green Universal PCR Master Mix (Bio-rad). The relative gene
expression levels were calculated using the 11Ct method
as described (Catalano et al., 2015). Primers are listed in
Supplementary Table 2.
Statistical Analysis of Experimental Data
Data were analyzed for statistical significance using two-tailed
student’s Test using GraphPad-Prism5 (GraphPad Software, Inc.,
San Diego, CA). Standard deviations (S. D.) are shown.
Classical MD Simulations
Of the 17 tested molecules (Figure 1, Supplementary Figure 3)
obtained by both protocols of VS (four from the structure-based
strategy and the rest by the ligand-based strategy as reported
in Supplementary Table 1) five resulted to be active in the in
vitro tests. These latter were also docked to the WT ERα using
the XP protocol. All active molecules were subjected to MD
simulations in complex with the WT and Y537S ERα variants.
Additionally, compound 19, showing the most promising results
in experimental tests, was also docked and simulated in complex
with Y537N and D538G ERα.
Physiological protonation states of ERα were already
determined previously (Pavlin et al., 2018) using the webserver
H++ (Anandakrishnan et al., 2012). Parm99SB AMBER force
field (FF) with ILDN modification was employed for the protein
(Wickstrom et al., 2009; Lindorff-Larsen et al., 2010), and the
general Amber FF (GAFF) (Wang et al., 2004) was used for
ligands. ESP charges (Bayly et al., 1993) were calculated by
performing geometry optimizations of the ligands at Hartree-
Fock level of theory using a 6-31G∗ basis set with the Gaussian
09 software (Frisch et al., 2016) and were later transformed in
RESP charges with the Antechamber module of Ambertools16
(Wang et al., 2006). Since the dockings were performed on
monomers, while the LBD in physiological conditions is a dimer,
we built each dimer by superimposing the monomer on each of
the two dimers of the corresponding mERα conformation from
our previous work (Pavlin et al., 2018).
Each systemwas solvated using TIP3P waters (Jorgensen et al.,
1983) in a truncated octahedron box with minimum distance
of 12 Å between solute and the edge of the box, leading to a
total of ∼95,000 atoms. MD simulations were performed with
FIGURE 2 | Inhibition of Y537S ERα activation exerted by the compound 19 in MDA-MB-231 breast cancer cells. (A) Immunoblotting showing exogenous ERα
protein expression in ERα-negative MDA-MB-231 breast cancer cells transiently transfected with an empty vector (e. v.), YFP-WT or YFP-Y537S ERα expression
vectors. GAPDH was used as a control for equal loading and transfer. (B) ERα-transactivation assay in MDA-MB-231 cells transiently transfected with YFP-WT or
YFP-Y537S ERα expressing vectors plus an ERE-luciferase reporter (XETL), and treated with vehicle (-) or the different compounds (6-22), as indicated. Data are
reported as fold change relative to WT-ERα expressing cells. (C) MTT cell viability assay in MDA-MB-231 cells treated with vehicle (-) or the different compounds (9,
13, 19, 20, 21, 100µM), as indicated for 24 h. Results are expressed as fold change relative to vehicle-treated cells. The values represent the mean ± S. D. of three
different experiments, each performed in triplicate. n. s., non-significant; *P < 0.05; **P < 0.005; ***P < 0.0005; ****P < 0.00005.
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GROMACS 5.0.4 (Abraham et al., 2015). An integration time
step of 2 fs was used and all covalent bonds involving hydrogen
atoms constrained with the LINCS algorithm (Hess et al.,
1997). Particle Mesh Ewald algorithm (Darden et al., 1993) was
used in order to account electrostatic interactions. Simulations
were performed in the isothermal-isobaric NPT ensemble, at
a temperature of 310K, under control of a velocity-rescaling
thermostat (Bussi et al., 2007). Preliminary energy minimization
was done with the steepest descend algorithm. Next, all systems
were heated to the final temperature of 310K using 40 steps of
simulated annealing (0-90K in steps of 5 K/25 ps; 90-310K in
steps of 10 K/25 ps). WT ERα models underwent 300 ns long
classical MD simulations (last 200 ns were used for analysis),
while mERα ones underwent 400 ns long simulations and last
300 ns were used for further analysis.
Metadynamics
In order to further refine the binding poses and better dissect
the impact of the kinetic properties on efficacy and selectivity,
we performed FF-based Metadynamics (MTD) simulations of
AZD and 19. In particular, MTD runs of 60–130 ns were done
to refine the binding pose and study ligand dissociation with
GROMACS 5.0.4 using the PLUMED 2.0 plugin (Tribello et al.,
2014). Two collective variables (CVs) were used: the first CV
(CV1) describes the number of either hydrogen bonds (AZD)
or hydrophobic contacts (19) between the ligands and the LBC,
computed as a coordination number; the second CV (CV2)
corresponds to the distance between the center of masses (COM)
of the protein and the ligand. Gaussian hills having a height of
0.6 kJ/mol in all systems, while the widths of 0.06 and 0.015
(AZD), 0.40 and 0.025 (19), were added, respectively, for CV1
and CV2 every 4 ps of MD. A harmonic wall was used to
restrain the exploration of the FES on CV2 at the value of 3.5 nm.
Three replicas of the MTD simulations were performed, starting
from different frames as extracted from the equilibrated MD
trajectory and the uncertainty of the dissociation free energy
barriers (1G#b) were estimated from the standard deviation of the
barriers obtained out of the three replicas, following a protocol
adopted in previous studies (Bisha et al., 2013; Sgrignani and
Magistrato, 2015; Spinello et al., 2018, 2019a).
Simulation Analysis
Cluster analysis and root mean square deviation (RMSD) of
the MD trajectories were done with the g_cluster tool, based
on the Daura et al algorithm (Daura et al., 1999), and g_rms,
as implemented in the GROMACS 5.0.4 program (Abraham
FIGURE 3 | Impact of compound 19 on activation of WT, Y537N, and D538G ERα in MDA-MB-231 breast cancer cells. (A) Immunoblotting showing exogenous ERα
protein expression in ERα-negative MDA-MB-231 breast cancer cells transiently transfected with an empty vector (e. v.), YFP-WT, YFP-Y537N, YFP-Y537S, or
YFP-D538G ERα expressing vectors. GAPDH was used as a control for equal loading and transfer. (B) ERα-transactivation assay in MDA-MB-231 cells transiently
transfected with YFP-Y537N, YFP-Y537S, or YFP-D538G ERα expressing vectors plus an ERE-luciferase reporter (XETL), and treated with vehicle (-) or the
compound 19 at 100µM. Data are reported as fold change relative to WT-ERα expressing cells. (C) ERα-transactivation assay in MDA-MB-231 cells transiently
transfected with YFP-WT plus XETL plasmid, and treated with vehicle (-) or the compound 19 (100µM) in the presence or not of 17β-estradiol (E2, 10 nM). Data are
reported as fold change relative to vehicle (-)-treated cells. The values represent the mean ± S. D. of three different experiments, each performed in triplicate. n. s.,
non-significant; **P < 0.005; ***P < 0.0005. (D) Immunoblotting showing ERα protein expression in MDA-MB-231 breast cancer cells transiently transfected with
YFP-Y537S ERα expressing vector and treated with the compound 19 (100µM) at the indicated time. GAPDH was used as a control for equal loading and transfer.
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et al., 2015). Molecular Mechanics Generalized Born Surface
Area (MM-GBSA) free energy calculation were performed with
the MM_PBSA.py tool of Amber 18 program, following a
procedure successfully applied in previous studies (Spinello et al.,
2019a,c). Visualization of the MD trajectories was done with the
VMD program (Humphrey et al., 1996), while the images were
prepared using UCSF Chimera1.12 visualization tool (Pettersen
et al., 2004).
Correlation Analysis
The covariance matrices were constructed from the atoms
position vectors upon an RMS-fit to the starting configuration
of the MD run as to remove the rotational and translational
motions. Each element in the covariance matrix is the covariance
between atoms i and j, defining the i, j position of the matrix. The








where −→r i and
−→r j are the position vectors of atoms i and
j, and the brackets denote an average over the sampled time
period. The diagonalization of the covariance matrix leads to
a set of orthogonal collective eigenvectors, each associated to
a corresponding eigenvalue. The eigenvalues denote how much
each eigenvector is representative of the system dynamics.
The cross-correlation matrices (or normalized covariance
matrices) based on the Pearson’s correlation coefficients (CCij)
were calculated with the cpptraj module of Ambertools 18 from
the calculated covariance matrices. Each element of the cross-
correlation matrix in the i,j position corresponds to a Pearson’s
CCij, i.e., the normalized covariance between atoms i and j
























here the normalization factor is the product between the
standard deviations of the two position vectors. As a result,
CCij range from a value of −1, for a totally negatively
correlated motion between two atoms, and a value of +1, which
instead means a positively correlated lockstep motion. Here
we have also calculated the correlation scores (CSs) between
each LBD helix and all the others, dividing each as depicted
FIGURE 4 | Effects of compound 19 on WT and Y537S ERα activation in MCF-7 breast cancer cells. (A) Immunoblotting showing exogenous and endogenous ERα
protein expression in ERα-positive MCF-7 breast cancer cells transiently transfected with YFP-WT or YFP-Y537S ERα expressing vectors. GAPDH was used as a
control for equal loading and transfer. (B) ERα-transactivation assay in MCF-7 cells transiently transfected with YFP-WT or YFP-Y537S ERα expressing vectors plus
an ERE-luciferase reporter (XETL), and treated with vehicle (-) or the compound 19 at 100µM, as indicated. Data are reported as fold change relative to WT-ERα
expressing cells. (C) ERα-transactivation assay in MCF-7 cells transiently transfected with YFP-WT plus XETL plasmid, and treated with vehicle (-) or the compound
19 (100µM) in the presence or not of 17β-estradiol (E2, 10 nM). Data are reported as fold change relative to vehicle (-)-treated cells. The values represent the mean ±
S. D. of three different experiments, each performed in triplicate. n. s., non-significant; *P < 0.05; ***P < 0.0005.
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in Supplementary Figure 2 (Pavlin et al., 2018). Then, we
calculated the sum of CCij between the residues i belonging to the
helix I and the residues j belonging to the helix J. Importantly,
the values −0.6 < CCij < +0.6 were discarded in order to
eliminate the noise due to uncorrelated motions (Palermo et al.,
2016; Casalino et al., 2018) and the sum of the cross-correlation
score was divided by the product of the number of residues
contributing to the score as a correlation density.
RESULTS
In silico Screening and in vitro Studies
Building on our previous classification of structural traits
of drugs effectively targeting mERα (Pavlin et al., 2018),
we performed in silico screening on the structures obtained
from MD simulations of Y357S, Y537N, and D538G mutants
hosting AZD and FULV in the LBC. A detailed list of the
molecules tested as well as their docking score on each specific
target structure is reported in Supplementary Figure 3 and
Supplementary Table 1, respectively. Remarkably our newly
developed VS strategy allows not only to account for the distinct
conformations that the receptor can adopt at finite temperature,
as in the ensemble docking, but it also encompasses the induced
fit effects exerted by the binding of efficacious drugs to distinct
ERα isoforms (Spinello et al., 2019a). The best-ranked 17
compounds (6-22), that were binding to more than one ERα
isoform in VS, were then experimentally tested.
Namely, their effect on the transcriptional activity of the
mutant Y537S ERα was investigated in cell-based assays,
using a standard genomic transcriptional output method (i.e.,
the estrogen response element (ERE) - luciferase-based gene
transactivation system) for assessing their ability to bind ERα
and, subsequently, transactivate an ERE-mediated transcription,
allowing an assessment of the transcriptional responses of each
receptor separately. Thus, human ERα-negative MDA-MB-231
BC cells were cotransfected with either YFP-WT or YFP-Y537S
ERα expression vectors along with an ERE-luciferase reporter
plasmid (XETL) and treated with the vehicle or the selected
compounds (6-22). As shown in Figure 2A, cells expressed
similar levels of the 96 kDa protein representing the exogenously
added WT or Y537S mutant receptor tagged with YFP. In
line with previous results (Toy et al., 2013), reporter gene
transactivation assays showed that control basal activity of
Y537S ERα was more elevated than that of WT (Figure 2B).
Importantly, the tested compounds exerted different effects on
Y537S ERα transcriptional activity, with 9, 13, 19, 20, and
21 showing the highest efficacy in reducing the activity of
the Y537S mutant (76–57 % decrease) when used at 100µM
concentration. Hence, these were chosen to evaluate their
potential toxicity in MDA-MB-231 cells by using MTT cell
survival assay (Figure 2C). As a result, compounds 9, 13, 20,
and 21 markedly reduced cell viability even in MDA-MB-231
cells, whereas the compound 19 did not provoke any significant
effects at the dose tested. Thus, among these compounds, 19
represents the best-candidate for further studies. Among these
compounds, 9, 19, 20, and 21 share the same chemo-type of the
parent compounds AZD.
MDA-MB-231 BC cells transfected with Y537S-ERα vectors
and treated with compound 19 at increasing doses (from 1 nM
to 100µM) displayed a dose-dependent decrease of Y537S-ERα
transactivation, with the highest inhibition registered at 100µM
concentration (65 ± 10 % inhibition as compared to vehicle)
(Supplementary Figure 4).
To better clarify the activity of compound 19, we also
evaluated its ability to affect ERα transactivation in cells
expressing other two frequently-occurring mutations:
YFP-Y537N and YFP-D538G ERα mutations (Figure 3A).
Surprisingly, 19 has a smaller effect in hampering the
transactivation of these mutants (Figure 3B), stunningly
pinpointing its selectivity in antagonizing preferentially the
transcriptional activity of the Y537S ERα isoform.
Next, we inspected its effects on YFP-WT ERα expressing cells
in the presence/absence of 17β-estradiol (E2), the endogenous
ERα ligand (Figure 3C). As expected, E2 treatment was able
to trigger luciferase expression through the ERE interaction.
Notably its treatment with compound 19, while not significantly
altering WT-ERα transactivation, was associated with a drastic
reduction in E2-mediated effects. This suggests that ligand 19
may compete with E2 for the LBC. Interestingly, treatment with
19was not associated with a down-regulation of Y537S ERα levels
(Figure 3D).
To expand our investigation, the potency of the compound
19 in affecting Y537S ERα activity was also tested in ER+
MCF-7 BC cells bearing the YFP-WT and YFP-Y537S receptor.
These expressed a 66 kDa endogenous ERα, along with a 96
kDa receptor represent the exogenously added WT and mERα
tagged with YFP (Figure 4A). As previously shown for MDA-
MB-231 BC cells, we found a significant increase of YFP-
Y537S receptor transcriptional activity as compared to that of
YFP-WT ERα and this induction was reduced upon exposure
to compound 19 (Figure 4B). In addition, 19 antagonized
FIGURE 5 | Effects of compound 19 on ERα target genes in YFP-Y537S ERα
expressing MDA-MB-231 breast cancer cells. Real time RT-PCR assay for
Trefoil Factor 1 (TTF1), cathepsin D (CTSD), cyclin D1 (CCND1) and c-Myc
(MYC) mRNA expression. The values represent the mean ± S. D. of three
different experiments, each performed in triplicate. n. s., non-significant; *P <
0.05; **P < 0.005; ***P < 0.0005.
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E2-mediated effects also in YFP-WT ERα MCF-7 expressing
cells, without exerting any action on basal WT ERα activity
(Figure 4C).
At a molecular level, ERα activation and association with
the ERE result in an enhanced expression profiles of a number
of downstream target genes, including those for trefoil factor
1/pS2, cathepsin D, cyclin D1, and c-Myc (Barone et al.,
2010). The biological correlation of the inhibition of Y537S
ERα transactivation induced by 19 is the down-regulation of
the classical estrogen-regulated genes in MDA-MB-231 cells
(Figure 5), confirming the binding of this antagonist to ERα,
well-fitting with in silico predictions.
Atomic-Level Understanding of Drugs
Efficacy
In order to identify the structural and dynamics features
responsible of the efficacy and the selectivity of compound 19
toward Y537S ERα, while being inefficacious and/or displaying
limited efficacy on WT, D538G and Y357N, we performed
extensive MD simulations of the five active molecules in complex
with the WT and Y537S ERα isoforms, starting from binding
poses obtained from docking simulations.
MD simulations revealed two important and common
structural traits among the inspected compounds, also shared
by AZD and FULV. All molecules occupy the binding cavity
FIGURE 6 | Binding of the five active molecules to Y537S ERα as compared with END, AZD, and FULV. (A) END; (B) AZD; (C) FULV; (D) compound 19; (E) 9; (F) 13;
(G) 20; (H) 21. Top panels show their placement in the ligand binding cavity, while bottom panels display a close view of E380 H-bond network induced by each
ligand. Inhibitors are shown in licorice with carbon atoms in purple color, while oxygen and nitrogen are shown in red and blue, respectively. Protein is depicted in gray
new cartoons for END, AZD, FULV, and blue, green, light green purple orange new cartoons for 19, 9, 13, 20, 21, respectively.
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protruding toward the H11-12 loop, which hosts the Y537S
variant (Figure 6). Three of them (9, 19, 20) establish π-π
interactions with W386 in WT (Supplementary Figure 5). Due
to their different shapes, each ligand engages distinct H-bonds
patterns (Supplementary Table 3). This network in compounds
13 and 20 involves residues G521, M528, and C530, while 9
and 21 persistently H-bond either to L346, similarly to AZD, or
to E419 and G420 (Supplementary Table 3). These results show
that the selected compounds can either bind in LBC (9 and 21)
or interact with H11-12 loop (13 and 20).
Conversely, 19 is the only ligand firmly anchored to E419
and L346 (Supplementary Table 3), at tract H-bonding to K529,
similarly to AZD in complex with to Y537S (Figure 6). This
H-bonding motif in our previous paper was indicated as an
essential signature of drug-efficacy. Nevertheless, 19 forms a
set of low-persistent H-bonds, underlying its high mobility
and the need for further optimization in order to improve its
efficacy. Surprisingly, compound 19 establishes a well-defined
and stable H-bond network only in one LBCs of WT ERα
(Supplementary Table 3).
FIGURE 7 | Binding of compound 19 to Y537N and D538G ERα as compared with END, AZD and FULV. Binding to Y537N: (A) END; (B) AZD; (C) FULV; (D)
Compound 19. Binding to D538G: (E) END; (F) AZD; (G) FULV; (H) Compound 19. Top panels show their placement in the ligand binding cavity, while bottom panels
display a close view of E380 H-bond network induced by each ligand. Inhibitors are shown in licorice with carbon atoms in purple color, while oxygen and nitrogen in
red and blue, respectively. Protein is shown in gray new cartoons for END, AZD, FULV, and in blue new cartoons for 19, respectively.
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Next, we inspected how the active drugs counteract the H-
bond network responsible of the ERα agonist-like conformation
induced by mERα (Supplementary Table 4, Figure 6). A
decrease of the E380-Y537S interaction, previously indicated as
structural signature of an intrinsic ERα activation, occurs with
all ligands, even if this is less effective than upon FULV or AZD
binding. What is more, E380, which strongly H-bonds to S537 in
the aggressive Y537S ERα variant, upon binding of 9, 19, and 21,
rearranges and engages persistent H-bond to L536. Additionally,
in the presence of 19, there is significant change in the H-bond
network of L536 backbone. While this latter strongly interacts
with backbone of L539 in the presence of all other compounds,
19 weakens it and, as a result, L536 H-bonds to the backbone
of L540 (Supplementary Table 4). Remarkably, 19 triggers
formation of these H-bonds only in Y537S, but not in WT ERα.
In both Y537N and D538G variants 19 establishes a H-bond
network in the binding cavity and in the H11-12 loop region
similarly to Y537S (Supplementary Tables 3, 4, and Figure 7).
Hence, 19 exclusively H-bonds to E419 in all mutants, while only
in Y537S can establish week H-bond to K529, similarly to AZD.
We have also calculated the binding free energy (1Gb)
(Table 1) of the five active compounds to WT, Y537S and, for
compound 19, also to the Y537N, D538G variants. Stunningly,
19 dissociates from one monomer of WT ERα due to the lack
of H-bonds, rationalizing its preference toward the pathogenic
variants. Instead, its 1Gb is similar in all tested mutants. All
other active ligands, but 20, display a slightly higher affinity
for WT ERα, and their 1Gb is slightly larger than that of
19 toward Y537S, most probably because of their larger size.
Nonetheless, the tested ligands do not strongly bind to the LBC,
as shown by a comparison of the calculated 1Gb compared to
that AZD. Thus, even small differences in the position of their
H-bonding moieties may result in the different binding poses
observed for 20 and 13. To monitor the impact of the distinct
ligands size on 1Gb, we also computed the ligand efficiency
(LE, Supplementary Table 5), calculated as 1Gb divided by the
number of non-hydrogen atoms. LE differences among ligands
are smaller than that of 1Gbs. 19 presents comparable LE for all
mutants tested. Interestingly, compounds 9, 20, 21 have a slightly
larger LE for Y537S than 19, suggesting that other features,
besides LE or 1Gb, may be important for ligand selectivity
toward the distinct ERα isoforms.
Structural Signatures of (m)ERα
Activation/Inactivation
The cross-correlation matrix calculated on the basis of the
Pearson correlation coefficients (CCij) was computed to
qualitatively identify the linearly coupled motions between
couples of residues along the MD trajectory. A simplified
version of this matrix, based on the sum of the of correlation
scores (CSs) between each structural elements of (m)ERα
(Supplementary Figure 2), has been calculated to decrypt the
correlation pattern in complex systems (Casalino et al., 2018),
among which ERα (Pavlin et al., 2018). In this analysis, a
positive/negative score corresponds to a positively (correlated) /
negatively (anti-correlated) motion.
In our previous study, the presence of a positive correlation
score between H12 and H3-H5 was taken as a structural
signature of Y537S ERα intrinsic activation. This was persistent
upon END binding, while only FULV and, partially, AZD
were able to remove it, in line with the proved activity of
these SERDs on the Y537S mutant (Fanning et al., 2016).
Hence, we also inspected if the ligands differently affect the
internal cross-correlation map. All compounds binding to
Y537S remove the contacts between H12 and H3, reducing,
in most cases, the cross-correlation score in both monomers
TABLE 1 | Binding free energies (1Gb, kcal/mol) of the ligands 9, 13, 19, 20, and 21.
WT Y537S Y537N D538G
A B A B A B A B
Endoxifen −51.7 ± 3.6 −46.9 ± 3.3 −45.6 ± 3.5 −45.2 ± 3.5 −43.8 ± 3.3 −49.9 ± 4.3 −47.1 ± 3.4 −50.5 ± 3.6
AZD−9496 −45.2 ± 3.6 −43.9 ± 3.7 −42.9 ± 3.7 −53.7 ± 7.7 −45.1 ± 4.1 −42.9 ± 3.9 −45.1 ± 4.0 −43.7 ± 4.3
Fulvestrant −69.0 ± 6.4 −66.9 ± 6.2 −65.1 ± 5.1 −76.0 ± 5.6 −68.2 ± 6.1 −66.6 ± 5.7 −63.5 ± 6.0 −69.7 ± 6.0
9 −42.7 ± 4.2 −36.7 ± 4.4 −36.9 ± 5.7 −37.3 ± 4.6 / / / /
13 −44.8 ± 4.3 −42.6 ± 3.3 −41.4 ± 3.2 −45.2 ± 4.6 / / / /
19 −21.3 ± 7.2* −40.9 ± 8.1 −32.3 ± 5.8 −32.3 ± 6.2 −32.9 ± 3.6 −43.0 ± 6.7 −30.8 ± 5.7 −46.8 ± 6.0
20 −38.6 ± 3.3 −35.1 ± 2.6 −40.0 ± 2.9 −38.9 ± 5.0 / / / /
21 −45.4 ± 3.3 −42.5 ± 3.8 −43.6 ± 3.2 −39.2 ± 3.0 / / / /
Absolute values of molecular mechanics Generalized bond surface are (MM-GBSA).‡









*Ligand exits from the binding pocket.
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(Supplementary Figure 6). Moreover, compound 19 decreases
these contacts also when binding to Y537N and, to a minor
extent, to D538G (Supplementary Figures 7, 8). Conversely, in
WT ERα a smaller positive correlation among H5 and H12
can be observed only for (20 and 21; Supplementary Figure 9).
In order to capture more quantitatively the relative differences
among the activity exerted by these ligands we also analyzed
how H12 correlates with all other ERα structural elements in
the presence of the distinct active compounds. This analysis
clearly shows that ligands 9 and 20 present a cross-correlation
FIGURE 8 | Sum of per-residue cross-correlation coefficients. Left and right columns refer to monomers A and B, respectively. From top to bottom: WT (in complex
with END, AZD, FULV, and 19), WT (with 9, 13, 20, and 21), Y537S (with END, AZD, FULV, and 19), Y537S (with 9, 13, 20, and 21), Y537N, and D538G (in complex
with END, AZD, FULV, and 19). END, AZD, FULV, and compounds 9, 13, 19, 20, 21 are shown as black, red, green, blue, orange, purple, cyan, and brown lines,
respectively.
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coupling between H12 and H4-H5 higher or similar to END at
least in one Y537S ERα monomer, while 19 effectively reduces
this positive correlation in both monomers. This correlation
coupling is completely abolished in Y537N and reduced even in
D538G (Figure 8), pointing to an activity of 19 also against these
mutants, even if to a minor extent.
As a result, 19 appears to reduce the transcriptional activity of
Y537S cells thanks to its capability of binding in the LBC of both
LBDmonomers only in the mERαs, where it establishes H-bonds
with E415, L346 and K529, similarly to AZD.
Kinetic Characterization of Active
Compounds
Since increasing evidences pinpoint the dissociation free energy
barriers (1G#d) of a ligand from its binding cavity to be strongly
entwined with the residence time and, thus, with drugs’ efficacy
(Magistrato et al., 2017), the observed preferential activity of
19 toward Y537S ERα fostered the investigations of its kinetic
properties as compared to those of AZD.
The free energy surface (FES) obtained from MTD
simulations inducing the dissociation of AZD from the
LBC of Y537S ERα shows a wide minimum at Center of Mass
(COM) distance between ligand and protein at ∼1.2 nm, which,
instead, spans the coordination number (CN) 0.2-0.4. A second,
narrower, minimum appears at CN around 0 and COM distance
≥ 2.5 nm. By inspecting two-dimensional FES plots of both
CVs one can estimate a 1G#d of 14.1 ± 2.0 kcal/mol for AZD
dissociation (Figure 9A, Supplementary Figures 10, 11, and
Supplementary Table 6). The main barrier observed for AZD
dissociation is due to the breaking of its H-bond interactions
between the carboxylic group of AZD with K529 and C530.
These, therefore, appear as pivotal residues for increasing the
residence time of this drug in the LBC and possibly its efficacy.
On the other hand, FES for the dissociation of 19 reveals a
rather wide minimum at CN = 0.2–0.4, lying at higher distance
(COM) between ligand and the LBC as compared to AZD (1.5–
1.7 nm) (Figure 9B). The second minimum is located in a similar
position to that of AZD. In this case, however, the 1G#d is rather
small (3.7 ± 1.9 kcal/mol) (Supplementary Figures 10, 11 and
Supplementary Table 6) and it is associated to the breaking of
the H-bond between the hydroxyl group of the ligand and the
E418 residue. This latter, therefore, appears to be a distinctive
feature of this ligand.
These simulations pinpoint the most important substituents
of the ligand that may contribute to improve the kinetic
properties of the drugs, and the residues of the LBC that must
be engaged in specific interactions for the discovery of mutant-
specific anti-estrogen compounds.
DISCUSSION
Breast cancer remains the most diagnosed (1 over 8) and the
second leading cause of cancer induced mortality in women. The
majority (70 %) of BC is hormone dependent and its proliferation
relies on the presence of ERα, which has a pro-oncogenic
effect in the presence of estrogens. The gold standard treatment
in this type of BC is the hormone adjuvant therapy, which
either suppresses estrogen production (aromatase inhibitors) or
modulates/degrades the ERα (SERMs/SERDs). The prolonged
exposure to these therapies, usually administered consecutively
for 5–10 years’ time-frame, leads to resistance in half of all
luminal BCs after 5 years, in spite of the ERα expression (Toy
et al., 2017; Fanning et al., 2018; Busonero et al., 2019; Spinello
et al., 2019b).
While the genomic profile of inherited and somatic alterations
characterizing each type of BC is well-established, the evolution
of the BC’s genomic landscape under the evolutionary pressure
of systemic therapies is not clearly understood. As well as how
this landscape impacts on the clinical outcome of endocrine
therapies remains poorly characterized and is currently object of
intense research efforts. Resistance onset is, in fact, responsible
of refractory BCs and of an increased mortality rate. In this
worrisome scenario, the therapeutic options to intervene with
personalized treatments based on the patients’ evolution of the
genomic profiles remains a daunting challenge. This has spurred
substantial efforts to characterize the phenotype responsible of
drug resistance and propose innovative therapeutic options.
FIGURE 9 | Free energy surface maps from metadynamics simulations for the dissociation of AZD (A) and compound 19 (B) from the ligand binding cavity. On x axis
is coordination number (H-bond for AZD and hydrophobic interactions for 19) and on y axis is COM distance between ligand and receptor. Color scale represents free
energy values in kJ/mol. In black squares are encircled structures corresponding to the ligand bound state (ground state), the transition state.
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Distinct studies indicated that frequent mutations present
in the loop connecting H11 and H12 of the LBD trigger
the acquisition of an intrinsically active (agonist-like) ERα
conformation, even in the absence of E2. This conformation
remains even in the presence of SERMs (Fanning et al.,
2016; Pavlin et al., 2018). Our recent computational attempt
to identify the key common structural traits that drugs
should possess in order to effectively fight resistant BCs
was the grounding knowledge for the present study. Indeed,
here we carried out in silico screening on the structural
scaffolds of the Y537S, Y537N, and D538G mutants
adapted to known mERα degraders (AZD and FULV),
seeking for the structural elements able to protrude toward
loop connecting H11-H12. This should allow the ligand
to counteract the intrinsic and mutant dependent ERα
activation (Pavlin et al., 2018).
From a consensus docking study, we selected 17 molecules
(Supplementary Figure 3) effectively binding in at least two
mutants, among which five resulted to be active on BC cell
lines. Some of them were known to be active also on other
targets and diseases (Supplementary Table 7). Among these
compounds, 19 was selective exclusively toward those expressing
Y537S (and to aminor extent to Y537N,D538G) ERα (Figures 2–
4). In spite of its ability to block the transcriptional activity
of the receptor only in the high µM range, thus requiring
further optimization, the structural scaffold of compound 19
encompasses all the motifs required by an active and mutant-
specific drug-candidate. Namely, 19 forms number of H-
bonds in the ligand binding cavity (L346 and E419) and
with K529. Conversely, E380, a key residue involved in the
structural transition toward an agonist-like state of the receptor,
persistently H-bonds to H377. This is a previously annotated
structural feature able to impede the pro-oncogenic effect of
resistant phenotypes. Indeed, compound 19, to the best of
our knowledge, is the only mutant specific modulator of ERα
transcriptional activity identified so far. However, its 1Gb and
1G#d are remarkably smaller than the parent AZD compound. A
detailed comparison among the residues, which optimize these
thermodynamics and kinetic properties of the 19 with respect
to those of AZD is informative for future knowledge-based
drug-design efforts aimed at discovering drug-candidates with
superior efficacy.
Since ESR1 mutations are potential clinical biomarkers to
guide therapeutic decisions, identification of small molecules
able to block proliferation of metastatic tumors expressing
one prevalent mERα resistant phenotypes may result in
counteracting, preventing and/or delaying their occurrence in
early disease stage. In this scenario, our study contributes to
move a step forward toward precision and personalized medicine
tailored against metastatic and resistant ER+ BCs.
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